16. Drug-Induced Liver Disease
- E. Jenny Heathcote MB, BS, MD, FRCP, FRCP(C)2,3,4,5
Published Online: 4 SEP 2012
DOI: 10.1002/9781118314968.ch16
Copyright © 2012 John Wiley & Sons, Ltd
Book Title
Hepatology: Diagnosis and Clinical Management
Additional Information
How to Cite
Lilly, L. B. (2012) Drug-Induced Liver Disease, in Hepatology: Diagnosis and Clinical Management (ed E. J. Heathcote), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118314968.ch16
Editor Information
- 2
Francis Family Chair in Hepatology Research, Toronto, Ontario, Canada
- 3
University of Toronto, Toronto, Ontario, Canada
- 4
Patient Based Clinical Research Division, Toronto Western Research Institute, Toronto, Ontario, Canada
- 5
University Health Network/Toronto Western Hospital, Toronto, Ontario, Canada
Publication History
- Published Online: 4 SEP 2012
- Published Print: 12 OCT 2012
ISBN Information
Print ISBN: 9780470656174
Online ISBN: 9781118314968
- Summary
- Chapter
- References
Keywords:
- hepatotoxicity;
- hepatitis;
- cholestasis;
- liver failure
Summary
Drug-induced liver disease (DILD), ranging in presentation from mildly abnormal liver biochemistry to fulminant hepatic failure, is a serious and growing problem in modern medicine. More than 1000 medications have been implicated, and with the addition of new agents to formularies every year there is growing potential for further hepatotoxicity, particularly as the number of patients taking multiple medications continues to increase. In chronically or critically ill patients, co-morbidities, which may themselves be associated with deranged liver biochemistry, make determination of the role of DILD all the more difficult, yet all the more important. A systematic and organized approach to this challenging problem is keytominimizing the consequences of this all too common pharmacological complication.